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Purpose: The purpose of this study is to evaluate and compare recurrence rates upon using 
mitomycin C (MMC) with limbal-conjunctival autograft for treating recurrent pterygia.
Methodology: An interventional, prospective, comparative clinical study was performed in 
30 eyes (26 patients) with recurrent pterygia, allocated into two groups: Group A (19 eyes) 
operated by pterygium excision and limbal-conjunctival autograft transplantation (L-CAT) 
without MMC and Group B (20 eyes) operated with injection of 0.1 mL of MMC 0.15 mg/mL 
1 month before L-CAT surgery. Exclusion criteria included patients with symblepharon, 
  cicatricial conjunctival diseases, limbal stem cell deficiency, and other intraocular diseases.
Results: A total of four cases of recurrences for Group A (P = 0.012) and one case of recur-
rence for Group B (P , 0.001) were recorded.
Conclusions: Preoperative injection of MMC in low dose and concentration improves the 
results of L-CAT in recurrent pterygium.
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Introduction
A pterygium is a wing-shaped growth of fibrovascular conjunctiva onto the cornea. 
Its incidence varies across geographical locations. Several hypotheses have been 
ascribed to its etiology. Currently, it is believed that the pterygium is a growth disorder 
characterized by conjunctivalization of the cornea due to localized ultraviolet-induced 
damage to the limbal stem cells. Aggressive pterygial fibroblasts are also responsible 
for corneal invasiveness.1
The indications for surgery include reduced vision due to encroachment on the 
visual axis and irregular astigmatism, chronic irritation, recurrent inflammation, restric-
tive ocular motility, and cosmetic purposes. Numerous surgical techniques including 
bare sclera excision with or without the use of adjuncts like beta irradiation, thiotepa 
eye drops, intra- or postoperative mitomycin C (MMC), amniotic membrane trans-
plantation, and conjunctival autograft have been described.2 Pterygium represents a 
local limbal deficiency. Thus, inclusion of limbal epithelium in the conjunctival graft 
for pterygium surgery would achieve better anatomic and functional reconstruction 
after pterygium removal by restoring barrier function of the limbus.3
MMC is an antitumor antibiotic that was first isolated from Streptomyces caespitosus 
by Wakaki et al4 in 1958, and it acts by inhibiting DNA synthesis. The mechanism of 
action seems to be inhibition of fibroblast proliferation at the level of the episclera.5 
The benefit of MMC is that it has the prolonged if not permanent effect which indi-
cates its toxicity to the cells.6 Adjunctive MMC for pterygium surgery was first Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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described by Kunitomo and Mori7 in Japan in 1963 and in 
the United States by Singh et al8 in 1988 as postoperative 
topical MMC of concentration ranging from 0.4 to 1 mg/mL.
Although multiple studies have reported recurrence 
rates of ∼5%–12% with the use of topical MMC,9,10 this 
technique has been associated with rare but significant con-
junctival, sclera, and corneal toxicity.9 In an attempt to 
decrease ocular morbidity, intraoperative use of MMC was 
suggested.11 Advantages of this technique include decreasing 
the MMC dosage and application directly to the area of 
pathology rather than to the entire ocular surface. A combined 
pterygium removal with intraoperative MMC and conjunc-
tival autografting was described.12
The purpose of this study was to evaluate the role of 
MMC injection directly into the surgical site 1 month before 
limbal-conjunctival autograft transplantation (L-CAT) in 
recurrent pterygia.
Subjects and methods
A prospective, comparative, interventional clinical study was 
carried out. This study included 39 eyes (33 patients; 
27 unilateral and 6 bilateral) complaining of recurrent 
pterygium of variable size, duration, and number of recur-
rences, which are mentioned in Table 1. All recurrences 
happened at least 3 months prior to the MMC injection. 
Surgeries carried out prior to our study were bare sclera tech-
nique for 28 eyes and conjunctival rotational flap for 11 eyes. 
None had free conjunctival graft or MMC application.
Exclusion criteria were patients with symblepharon, 
cicatricial conjunctival diseases, limbal stem cell deficiency 
diseases, and other intraocular diseases. Subjects were 
recruited from outpatient clinic of Kasr El Aini University 
and International Eye Hospital in Cairo. They were allocated 
into 2 groups: Group A included 19 eyes of 15 patients 
(11 males and 4 females; 4 bilateral and 11 unilateral) all 
operated by pterygium excision and free autologous limbal-
conjunctival autograft transplantation (L-CAT) without 
MMC and Group B included 20 eyes of 18 patients (9 males 
and 9 females; 2 bilateral and 16 unilateral) all had injection 
of MMC 1 month before L-CAT surgery.
Preoperative assessment
Both uncorrected and best-corrected visual acuities (UCVA 
and BCVA, respectively) were measured using decimal 
system with equivalent standard logarithm of the minimum 
angle of resolution values. Full ophthalmic examination was 
performed including intraocular pressure measurement with 
Goldmann’s applanation tonometry and indirect ophthalmos-
copy for fundus.
Pterygium examination was performed to identify its nature 
(fleshy or fibrotic) and its corneal encroachment. It was graded 
according to growth onto the cornea: Grade 1 (0–2 mm), 
Grade 2 (2–4 mm), and Grade 3 (more than 4 mm).
surgical technique
•	 Anesthesia was given by peribulbar injection of   Debocaine® 
2.0% (lidocaine HCL 20 mg; El Nasr   Chemicals, Cairo, 
Egypt) and Marcaine® (bupivacaine HCL 0.5%; 
AstraZeneca AB, Sodertartalje, Sweden) in a ratio of 1:1. 
Subconjunctival injections at the pterygium and graft 
sites help in dissection.
•	 Dissection of the pterygium head was carried out with a 
crescent knife.
•	 Resection was carried out from the underlying sclera or 
medial rectus.
•	 Excision of the whole pterygium was carried out followed 
by hemostasis using wet-field cautery.
In Group A, a superficial circumferential incision (around 
100-µm depth) in the cornea, 0.5-mm from the superotem-
poral limbus, was performed to include limbal epithelium to 
the conjunctival graft. The limbal-conjunctival graft was 
placed in the correct orientation in the scleral bed and sutured 
using eight 8/0 vicryl anchoring sutures, conjunctiva-
episclera–conjunctiva.
•	 Dressing was carried out with antibiotic-steroid mixtures 
ointment plus eye cover.
•	 Postoperative treatment given was mixed antibiotic-steroid 
drops (DexafloxTM, ofloxacin 3.0 mg/mL and dexametha-
sone 1.0 mg/mL; Jamjoom, Jeddah, Saudi Arabia) and 
ointment (Tobradex®, tobramycin 0.3 mg/mL and dex-
amethasone 1 mg/mL; Alcon, Cairo, Egypt) with gradual 
tapering of medications over 1 month postoperatively.
In Group B, 1 month before carrying out the previously 
described surgery, under an operating microscope and by 
using a 30-gauge needle, 0.2 mL of 1% lidocaine anesthetic 
Table 1 showing descriptive data for both groups
Data in mean ± SD Group A Group B
Number of recurrences 1.33 ± 0.2 1.93 ± 0.3
Duration passed since last 
recurrence (months)
4.3 ± 0.5 5.1 ± 0.2
Length (mm) 7.00 ± 2.66 5.23 ± 1.56
Width (mm) 3.9 ± 0.94 3.56 ± 0.62
Grade 1.73 ± 0.79 1.60 ± 82Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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with epinephrine was injected into the head of the pterygium 
at the limbus, which caused mild swelling of the conjunctiva. 
Five minutes after the lidocaine injection, subconjunctival 
injection at site of pterygium was done using a 30-gauge 
needle on a tuberculin syringe containing MMC (0.1 mL of 
0.15 mg/mL), followed by previously described eye drop and 
ointment for 1 week.
evaluation
Patients were examined at postoperative days 1, 7, 14, and 30, 
then every 3 months for 1 year with the exception of 9 eyes 
which completed only 6 months follow-up. Evaluation is for 
the occurrence of any complications, such as corneal epithelial 
toxicity, sclera thinning, or graft sloughing, and for recur-
rences. Figures 1 and 2 show photographs for 2 cases of Groups 
A and B, respectively. Recurrence was defined as progressive 
fibrovascular corneal encroachment after surgery.
Results
Data were coded and entered using the statistical package 
SPSS (version 17; SPSS Inc, Chicago, IL). Data were sum-
marized in percentage for qualitative variables. Comparisons 
between groups were done using χ2 test. P value # 0.05 was 
considered statistically significant.
Descriptive results
The study included 39 eyes of 33 patients (20 males and 
13 females). Age ranged from 15 to 65 years (mean 
43 ± 1.5 years) for Group A and from 27 to 59 years 
(mean 39 ± 2 years) for Group B.
Visual acuity
Preoperatively, mean UCVA measured for Groups A and B 
was 0.6 ± 0.1 and 0.56 ± 0.2, respectively. Mean BCVA 
measured for Groups A and B was 0.9 ± 0.07 and 1 ± 0.1, 
respectively.
Postoperatively at 1 month follow-up, mean UCVA 
measured for Groups A and B was 0.58 ± 0.08 and 
0.57 ± 0.15, respectively. Mean BCVA measured for Groups 
A and B was 0.87 ± 0.09 and 1.1 ± 0.08, respectively.
intraocular pressure
In Group A, the mean of 16 ± 0.5 mm Hg measured preopera-
tively changed postoperatively at 1 month follow-up to a mean 
of 15.8 ± 0.2 mm Hg. In Group B, the mean of 17.1 ± 0.4 mm Hg 
measured preoperatively changed postoperatively at 1 month 
follow-up to a mean of 16.9 ± 0.1 mm Hg.
recurrence
A total of four cases of recurrences were recorded for 
Group A, two at 3 months, one at 6 months, and one at 
12 months follow-up. One case of recurrence was recorded 
for Group B at 6 months follow-up.
incidence and P value
For Group A (19 cases), recurrence in 4 cases (21.1%) 
(P = 0.012, within the group) was observed. For Group B 
(20 cases), recurrence in 1 case (5%) (P , 0.001, within the 
group) was observed. The incidence of recurrence in Group A 
(4 cases) represents 80% of the total recurrent cases (5 cases) 
and in Group B (1 case) represents 20% of the total recur-
rent cases. Comparing the recurrence incidence of the two 
groups was favorable for Group B (only 1 case of recurrence), 
but P value was 0.134 (statistically nonsignificant); however, 
it should be stated that the low number of recurrences in this 
study may have affected the statistical results of comparing 
the 2 groups. Figure 3 shows a bar graph with number of 
recurrences for each group. Figure 1 Postoperative photograph of a case of Group A.
Figure 2 Postoperative photograph of a case of Group B.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Discussion
Pterygium, a worldwide degenerative corneal disease with 
a multifactorial etiology, is particularly common in tropical 
countries; the main complication of pterygium treatment is 
the unpredictable rate and timing of recurrences.13,14
The pterygia recurrence rate reported for patients treated 
with the bare sclera technique ranges from 24% to 89%,15,16 
whereas that reported after conjunctival autograft transplanta-
tion ranges from 1.6% to 33%.17,18 Amniotic membrane graft 
has been used as an alternative to conjunctival autograft 
transplantation, but the recurrence rate was still as high as 
37.5% for recurrent pterygia.19
Recurrent pterygium presents a significant surgical prob-
lem. Conjunctival shortening or symblepharon caused by 
multiple surgeries is especially challenging. Repeated surgi-
cal intervention in the limbal area causes severe barrier 
function destruction. To treat this complicated disorder, both 
suppression of the subconjunctival fibrosis and the recon-
struction of limbal barrier are required. Conjunctival trans-
plantation, lamellar keratoplasty, and limbal autograft 
transplant have been performed.20
In our study, the idea of using MMC 1 month preopera-
tively is to further decrease the dosage and morbidity associ-
ated with MMC when applied as topical or at time of surgery 
and to increase its effectiveness by applying the medication 
in a low concentration and low volume (0.1 mL of 0.15 mg/mL) 
subconjunctivally 1 month before surgery directly to the 
target tissue of activated fibroblasts.
Over a follow-up period of 12 months, four cases of 
recurrences (21.1%) for Group A and one case (5%) for 
Group B were reported. The superiority of using MMC could 
be explained by its inhibitor and toxic effect on fibroblasts, 
and using it 1 month before surgery maximized its effect 
despite the low dose used.21
Other studies showed rather similar results compared to 
this study. Donnenfeld and colleagues reported a recurrence 
rate of 6% on using MMC as a single injection 1 month before 
surgery with same concentration used in our study; however, 
all cases operated were primary pterygia.21 Boberg-Ans and 
colleagues22 proposed limbal autograft transplantation for 
the treatment of recurrent and advanced pterygia and reported 
a 7.4% recurrence rate. However, Gris and colleagues2 noted 
no recurrences after L-CAT. Akura and colleagues23 also 
investigated a smaller excision graft combination employing 
a 4-mm window excision with subepithelial pterygium 
removal, but used intraoperative MMC. Their technique 
produced no recurrences in 66 patients with follow up ranging 
from 6 to 32 months.
Conclusion
Although the combined MMC injection followed by L-CAT 
procedure is time consuming and technically demanding, our 
reported favorable recurrence rate encouraged us to use this 
technique for recurrent pterygium treatment.
No broad consensus exists on the best treatment for recur-
rent pterygium. Further long-term, multicenter, and random-
ized trials with higher numbers of cases are needed to 
determine the best treatment method. The results of our study 
show that both treatment modalities achieved success in the 
prevention of recurrent pterygium.
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